Kissei Pharmaceutical has filed a patent for a succinate salt compound that shows high storage stability and is suitable for use as a drug substance. The compound is useful for treating Parkinson’s disease, restless legs syndrome, hyperprolactinemia, and other related conditions. GlobalData’s report on Kissei Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kissei Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Kissei Pharmaceutical's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a succinate salt compound
A recently filed patent (Publication Number: US20230286998A1) describes a succinate salt of a compound called 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea. The patent claims that this salt can be represented by two different formulas, namely (A-1) and (A-2). The salt is also said to be crystalline and exhibits specific peaks at diffraction angles of 11.2±0.3 and 11.8±0.3 in a powder X-ray diffraction diagram. Additionally, it shows an endothermic peak at around 150°C in a thermogravimetric-differential thermal analysis chart. In a 13C solid-state NMR spectrum chart, the salt displays peaks at chemical shift values of 183.6±0.5, 180.5±0.5, 174.1±0.5, 170.0±0.5, 165.1±0.5, and 157.3±0.5.
The patent further claims that the salt can be characterized by two or three physical features selected from a group of features. These features include the aforementioned powder X-ray diffraction diagram peaks, the 13C solid-state NMR spectrum chart peaks, and a thermogravimetric-differential thermal analysis chart with an onset temperature of an endothermic peak at around 150°C.
The patent also discusses the use of the succinate salt in pharmaceutical compositions. These compositions can be used for the treatment or prevention of Parkinson's disease, restless legs syndrome, or hyperprolactinemia. The pharmaceutical compositions may contain the succinate salt along with at least one additional excipient.
In summary, the patent describes a specific succinate salt of a compound and its various physical characteristics, such as crystallinity and specific peaks in X-ray diffraction and NMR spectra. The patent also highlights the potential use of this salt in pharmaceutical compositions for the treatment or prevention of certain medical conditions.
To know more about GlobalData’s detailed insights on Kissei Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
